Skip to main content
Premium Trial:

Request an Annual Quote

IP Update: Recent Patents Awarded to Max Planck, Phigenix, and More

Premium

Title: RNA Sequence-specific Mediators of RNA Interference

Patent Number: 8,632,997

Filed: Oct. 4, 2010

Lead Inventor: Thomas Tuschl, Max Planck Institute


Title: dsRNA-induced Specific and Non-specific Immunity in Crustaceans and Other Invertebrates and Biodelivery Vehicles for use Therein

Patent Number: 8,633,028

Filed: July 2, 2004

Lead Inventor: Paul Gross, Medical University of South Carolina


Title: Targeting PAX2 for the Treatment of Breast Cancer

Patent Number: 8,633,149

Filed: May 24, 2011

Inventor: Donald Carlton, Phigenix


Title: siRNA Targeting Histamine Receptor H1

Patent Number: 8,633,306

Filed: Aug. 10, 2011

Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)

The Scan

Boosters Chasing Variants

The New York Times reports that an FDA advisory panel is to weigh updated booster vaccines for COVID-19.

Not Yet

The World Health Organization says monkeypox is not yet a global emergency, the Washington Post reports.

More Proposed for Federal Research

Science reports that US House of Representatives panels are seeking to increase federal research funding.

PLOS Papers on Breast Cancer Metastasis, Left-Sided Cardiac Defects, SARS-CoV-2 Monitoring

In PLOS this week: link between breast cancer metastasis and CLIC4, sequencing analysis of left-sided cardiac defects, and more.